Holen Sie sich die Stockscreener-App
233.87
0.06%
-0.13
Handel nachbörslich:
233.98
0.11
+0.05%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$234.00
Offen:
$235
24-Stunden-Volumen:
6.22M
Relative Volume:
1.11
Marktkapitalisierung:
$413.57B
Einnahmen:
$59.64B
Nettoeinkommen (Verlust:
$2.36B
KGV:
176.47
EPS:
1.3253
Netto-Cashflow:
$19.68B
1W Leistung:
+3.86%
1M Leistung:
+1.87%
6M Leistung:
+27.09%
1J Leistung:
+40.65%
1-Tages-Spanne:
$232.11
$237.19
1-Wochen-Bereich:
$225.29
$239.29
52-Wochen-Spanne:
$163.81
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Firmenname
Abbvie Inc
Sektor
Telefon
(847) 932-7900
Adresse
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Vergleichen Sie ABBV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
233.87 | 413.57B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
LLY
Lilly Eli Co
|
1,030.05 | 914.44B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
200.00 | 480.85B | 92.15B | 25.12B | 20.46B | 10.36 |
|
AMGN
Amgen Inc
|
343.99 | 184.00B | 35.89B | 7.01B | 11.54B | 12.94 |
|
MRK
Merck Co Inc
|
96.43 | 230.48B | 63.90B | 19.05B | 13.05B | 7.5596 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-11-04 | Herabstufung | DZ Bank | Buy → Hold |
| 2025-10-14 | Herabstufung | Erste Group | Buy → Hold |
| 2025-10-01 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-09-17 | Hochstufung | Berenberg | Hold → Buy |
| 2025-08-12 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-04 | Hochstufung | Argus | Hold → Buy |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-12-11 | Hochstufung | Goldman | Neutral → Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-07-25 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-05 | Herabstufung | Argus | Buy → Hold |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-22 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-11-08 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-08-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Underperform |
| 2022-05-06 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-02-28 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-03 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-03 | Bestätigt | Barclays | Equal Weight |
| 2022-02-03 | Bestätigt | BofA Securities | Neutral |
| 2022-02-03 | Bestätigt | Goldman | Neutral |
| 2022-01-13 | Eingeleitet | Redburn | Buy |
| 2022-01-12 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-11-23 | Hochstufung | Societe Generale | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-23 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Hochstufung | Argus | Hold → Buy |
| 2020-05-18 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Fortgesetzt | Morgan Stanley | Overweight |
| 2020-04-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Bestätigt | Cowen | Outperform |
| 2019-09-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-20 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-04-29 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
Alle ansehen
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
Is AbbVie’s 30% 2025 Surge Justified by Its Latest Drug Pipeline Wins? - Yahoo Finance
AbbVie Gets FDA Approval for Epkinly Combo for Relapsed Follicular Lymphoma - MarketScreener
AbbVie Announces U.S. FDA Approval of EPKINLY® in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma - Investing News Network
FDA approves AbbVie’s EPKINLY combination therapy for lymphoma By Investing.com - Investing.com Canada
FDA Approves AbbVie's EPKINLY for Follicular Lymphoma Treatment - GuruFocus
FDA Expands Approval for AbbVie's (ABBV) Epkinly in Lymphoma Tre - GuruFocus
AbbVie, Genmab win FDA label expansion for Epkinly (GMAB) - Seeking Alpha
Here's How Neuroscience Drugs Aided AbbVie's Top-line Growth in Q3 - Yahoo Finance
AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73 - simplywall.st
Analyst recommendations: Alphabet, Amazon, Microsoft, AbbVie, Comcast… - MarketScreener
How AbbVie Inc. stock performs in easing cycles2025 Earnings Surprises & Stepwise Trade Signal Implementation - newser.com
Enanta Pharmaceuticals Q4 revenue rises, helped by higher sales of AbbVie's MAVYRET/MAVIRET - TradingView
A Look Into AbbVie Inc's Price Over Earnings - Benzinga
AbbVie (ABBV) Gains Health Canada Approval for New Lupron Depot Dosage - GuruFocus
LUPRON DEPOT® new strength receives Health Canada Approval for the Treatment of Advanced Prostate Cancer - Investing News Network
Filmmaker helps AbbVie spread the word about leukaemia - pharmaphorum
AbbVie Stock Falls 4% -- What Investors Need to Know - Yahoo Finance
This Sector Is Suddenly Crushing the Broader Market. Should You Invest $1,000? - The Motley Fool
Why AbbVie Inc. stock appears on watchlists2025 Market WrapUp & Daily Price Action Insights - newser.com
Can AbbVie Inc. (Common Stock) (4AB0) stock retain market dominance2025 Year in Review & Growth Oriented Trade Recommendations - newser.com
Analyzing AbbVie Inc. with risk reward ratio chartsWeekly Stock Summary & Daily Stock Trend Reports - newser.com
Will AbbVie Inc. stock attract more institutional investorsJuly 2025 Earnings & Long Hold Capital Preservation Tips - newser.com
How AbbVie Inc. stock trades before earningsJuly 2025 Selloffs & Detailed Earnings Play Strategies - newser.com
Is AbbVie Inc. (4AB) stock undervalued after correctionJuly 2025 Spike Watch & Growth Focused Stock Reports - newser.com
AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73 - Yahoo Finance
Is AbbVie Inc. (4AB) stock a buy before earnings resultsJuly 2025 Retail & Smart Allocation Stock Tips - newser.com
How AbbVie Inc. (Common Stock) (4AB0) stock performs during market turbulenceJuly 2025 Analyst Calls & Daily Stock Trend Watchlist - newser.com
How reliable is AbbVie Inc. (4AB) stock dividend growthJuly 2025 PostEarnings & Consistent Return Investment Signals - newser.com
Will AbbVie Inc. stock announce special dividendFed Meeting & Safe Capital Allocation Plans - newser.com
AbbVie Inc 4AB Stock Analysis and ForecastMarket Liquidity Analysis & Learn the Secrets of Pro Traders - earlytimes.in
How higher bond yields impact AbbVie Inc. stockTrade Volume Summary & Fast Exit and Entry Trade Guides - newser.com
Will AbbVie Inc. stock beat EPS estimates2025 Top Gainers & Reliable Price Breakout Alerts - newser.com
AbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer - Investing News Network
AbbVie (NYSE: ABBV) debuts Second Winds CLL film; YouTube, Documentary+ in Dec 2025 - Stock Titan
Mubadala Investment Co PJSC reports share stake in Adobe, Verizon, dissolves in RTX, AbbVie - MarketScreener
Abbvie describes new LPAR1 antagonists - BioWorld MedTech
Is AbbVie Inc 4AB a good long term investmentExit Strategy Tips & Discover High-Return Stocks Before They Boom - earlytimes.in
AbbVie exits $1.5 billion longevity drug deal with Calico: report - Crain's Chicago Business
Why millennials buy AbbVie Inc. (Common Stock) (4AB0) stockQuarterly Profit Review & High Accuracy Buy Signal Tips - newser.com
Can AbbVie Inc. stock sustain revenue growthEarnings Growth Report & Stepwise Swing Trade Plans - newser.com
The Fight to Save the $2.7 Billion Botox Empire - Bloomberg.com
Is AbbVie Inc. stock undervalued vs historical averages2025 Geopolitical Influence & Proven Capital Preservation Methods - newser.com
Is AbbVie Inc. stock undervalued at current price2025 Technical Overview & Daily Stock Trend Watchlist - newser.com
Why AbbVie Inc. (4AB) stock stays on top picksWeekly Stock Summary & Consistent Income Trade Recommendations - newser.com
How AbbVie Inc. (4AB) stock benefits from digital adoptionWeekly Investment Recap & Capital Efficient Trading Techniques - newser.com
UCB’s Bimzelx and AbbVie’s Rinvoq Lead in EU5 Psoriatic Arthritis, Ankylosing Spondylitis, and Non-Radiographic Axial Spondyloarthritis Growth - The Manila Times
UCB’s Bimzelx and AbbVie’s Rinvoq Lead in EU5 Psoriatic - GlobeNewswire
What Wall Street predicts for AbbVie Inc. stock pricePortfolio Gains Summary & Reliable Price Breakout Alerts - newser.com
Argus Raises AbbVie's Price Target to $250 From $220 - MarketScreener
Can momentum traders help lift AbbVie Inc.IPO Watch & Consistent Growth Stock Picks - newser.com
AbbVie Announces 20 Recipients of Migraine Career Catalyst Award - Investing News Network
Finanzdaten der Abbvie Inc-Aktie (ABBV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.67%
2.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):